Research Article
BibTex RIS Cite
Year 2023, Volume: 5 Issue: 2, 148 - 152, 27.03.2023
https://doi.org/10.38053/acmj.1259439

Abstract

Thanks

Sayın Editörlere saygılarımı iletirim.

References

  • Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: Beyond traditional treatment approaches. J Thorac Oncol 2013; 8: 587–98.
  • Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S. Second‐line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP‐regimen) or cyclophosphamide, epirubicin, and vincristin (CEV‐regimen). Lung Cancer 2005; 48: 251–61.
  • Zhou T, Zhao Y, Zhao S. Comparison of the prognostic value of systemic inflammation response markers in small cell lung cancer patients. J Cancer 2019; 10: 1685–92.
  • Kang EJ, Lee SY, Kim HJ. Prognostic factors and skeletal‐related events in patients with small cell lung cancer with bone metastases at the time of diagnosis. Oncology 2016; 90: 103-11.
  • Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow‐up. Lung Cancer 2003; 39: 303–13.
  • Zalcman G, Tredaniel J, Schlichtholz B. Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer. Int J Cancer 2000; 89: 81–6.
  • Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.
  • Riedl J, Posch F, Königsbrügge O, et al. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. PLoS ONE 2014; 9: 111440.
  • Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Impact of red cell distribution width on future risk of cancer and all-cause mortality among cancer patients-The Tromsø Study. Haematologica 2015; 100: 387–9.
  • Ichinose J, Murakawa T, Kawashima M. Prognostic significance of red cell distribution width in elderly patients undergoing resection for non‐small cell lung cancer. J Thorac Dis 2016; 8: 3658–66.
  • Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G. Salemis NS. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study. J Clin Med Res 2013; 5: 121–6.
  • Chen GP, Huang Y, Yang X, Feng JF. A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer. Mediators Inflamm 2015; 2015: 854670.
  • Wang FM, Xu G, Zhang Y, Ma LL. Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma. Dis Markers 2014; 2014: 860419.
  • Petrella F, Casiraghi M, Radice D, et al. Prognostic value of the hemoglobin/red cell distribution width ratio in resected lung adenocarcinoma. Cancers 2021; 13: 710.
  • Wu F, Yang S, Tang X, Liu W, Chen H, Gao H. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer 2020; 11: 888–97.
  • Goldstraw P, Chansky K, Crowley J. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
  • Sun P, Zhang F, Chen C. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China. Oncotarget 2016; 7: 42650–60.
  • Tham T, Olson C, Wotman M. Evaluation of the prognostic utility of the hemoglobin‐to‐red cell distribution width ratio in head and neck cancer. Eur Arch Otorhinolaryngol 2018; 275: 2869–78.
  • Yakup B, Bediz K, Fatih G. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width. Int J Clin Oncol 2019; 24: 798-806.
  • Wu F, Yang S, Tang X, Liu W, Chen H, Gao H. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer 2020; 11: 888–97.
  • Petrella F, Casiraghi M, Radice D, et al. Prognostic value of the hemoglobin/red cell distribution width ratio in resected lung adenocarcinoma. Cancers 2021; 13: 710.
  • Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic significance of total lymphocyte count, neutrophil‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio in limited‐stage small‐cell lung cancer. Clin Lung Cancer 2019; 20: 117–23.

A new prognostic marker in small cell lung cancer: red cell distribution width ratio of hemoglobin

Year 2023, Volume: 5 Issue: 2, 148 - 152, 27.03.2023
https://doi.org/10.38053/acmj.1259439

Abstract

Aim: The ratio of hemoglobin (Hb) to red cell distribution width (RDW) (HRR) has been defined as an effective prognostic factor in various cancer types. The aim of this study is to investigate the prognostic role of HRR value in small cell lung cancer (SCLC).
Material and Method: A total of 1039 patients diagnosed with SCLC between 2010-2021 were included in the study. After exclusion of 199 patients without positron emission tomography-computerized tomography (PET-CT), age, gender, additional disease histories, smoking history, pathological stages, survival status, disease progression times, treatments applied, first hemoglobin obtained after diagnosis, red cell distribution width and ratios, and other laboratory parameters of 840 patients were recorded. The log-rank test and the Cox proportional hazards model were used to identify predictors of mortality.
Results: A total of 840 patients were included in the study. The median overall survival (OS) and the progression-free survival (PS) times of the patients were 9 months, and 7 months, respectively. The cut-off value for HRR was determined 0.580 (sensitivity 78.73%, specificity 37.88%). In this study, each one-unit increase in HRR reduces death and survival by 1.6 times detected, and it was revealed that HRR had a statistically significant effect on OS and PS. When the patients were divided into two as limited and extensive disease, there was a statistically significant difference between the groups in terms of OS (12-6 months) and PS (10-6 months), but no significant difference was found in terms of HRR between these two groups.
Conclusion: HRR is an easily accessible, inexpensive parameter that can be used as a prognostic marker in patients with SCLC.

References

  • Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: Beyond traditional treatment approaches. J Thorac Oncol 2013; 8: 587–98.
  • Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S. Second‐line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP‐regimen) or cyclophosphamide, epirubicin, and vincristin (CEV‐regimen). Lung Cancer 2005; 48: 251–61.
  • Zhou T, Zhao Y, Zhao S. Comparison of the prognostic value of systemic inflammation response markers in small cell lung cancer patients. J Cancer 2019; 10: 1685–92.
  • Kang EJ, Lee SY, Kim HJ. Prognostic factors and skeletal‐related events in patients with small cell lung cancer with bone metastases at the time of diagnosis. Oncology 2016; 90: 103-11.
  • Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow‐up. Lung Cancer 2003; 39: 303–13.
  • Zalcman G, Tredaniel J, Schlichtholz B. Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer. Int J Cancer 2000; 89: 81–6.
  • Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.
  • Riedl J, Posch F, Königsbrügge O, et al. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. PLoS ONE 2014; 9: 111440.
  • Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Impact of red cell distribution width on future risk of cancer and all-cause mortality among cancer patients-The Tromsø Study. Haematologica 2015; 100: 387–9.
  • Ichinose J, Murakawa T, Kawashima M. Prognostic significance of red cell distribution width in elderly patients undergoing resection for non‐small cell lung cancer. J Thorac Dis 2016; 8: 3658–66.
  • Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G. Salemis NS. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study. J Clin Med Res 2013; 5: 121–6.
  • Chen GP, Huang Y, Yang X, Feng JF. A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer. Mediators Inflamm 2015; 2015: 854670.
  • Wang FM, Xu G, Zhang Y, Ma LL. Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma. Dis Markers 2014; 2014: 860419.
  • Petrella F, Casiraghi M, Radice D, et al. Prognostic value of the hemoglobin/red cell distribution width ratio in resected lung adenocarcinoma. Cancers 2021; 13: 710.
  • Wu F, Yang S, Tang X, Liu W, Chen H, Gao H. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer 2020; 11: 888–97.
  • Goldstraw P, Chansky K, Crowley J. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
  • Sun P, Zhang F, Chen C. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China. Oncotarget 2016; 7: 42650–60.
  • Tham T, Olson C, Wotman M. Evaluation of the prognostic utility of the hemoglobin‐to‐red cell distribution width ratio in head and neck cancer. Eur Arch Otorhinolaryngol 2018; 275: 2869–78.
  • Yakup B, Bediz K, Fatih G. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width. Int J Clin Oncol 2019; 24: 798-806.
  • Wu F, Yang S, Tang X, Liu W, Chen H, Gao H. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer 2020; 11: 888–97.
  • Petrella F, Casiraghi M, Radice D, et al. Prognostic value of the hemoglobin/red cell distribution width ratio in resected lung adenocarcinoma. Cancers 2021; 13: 710.
  • Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic significance of total lymphocyte count, neutrophil‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio in limited‐stage small‐cell lung cancer. Clin Lung Cancer 2019; 20: 117–23.
There are 22 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Research Articles
Authors

Figen Öztürk Ergür 0000-0003-1915-714X

Ayperi Öztürk 0000-0003-0692-4784

Publication Date March 27, 2023
Published in Issue Year 2023 Volume: 5 Issue: 2

Cite

AMA Öztürk Ergür F, Öztürk A. A new prognostic marker in small cell lung cancer: red cell distribution width ratio of hemoglobin. Anatolian Curr Med J / ACMJ / acmj. March 2023;5(2):148-152. doi:10.38053/acmj.1259439

TR DİZİN ULAKBİM and International Indexes (1b)

Interuniversity Board (UAK) Equivalency:  Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show

Journal Indexes and Platforms: 

TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.


The indexes of the journal's are;

18596


asos-index.png

f9ab67f.png

WorldCat_Logo_H_Color.png

      logo-large-explore.png

images?q=tbn:ANd9GcQgDnBwx0yUPRKuetgIurtELxYERFv20CPAUcPe4jYrrJiwXzac8rGXlzd57gl8iikb1Tk&usqp=CAU

index_copernicus.jpg


84039476_619085835534619_7808805634291269632_n.jpg





The platforms of the journal's are;

COPE.jpg

images?q=tbn:ANd9GcTbq2FM8NTdXECzlOUCeKQ1dvrISFL-LhxhC7zy1ZQeJk-GGKSx2XkWQvrsHxcfhtfHWxM&usqp=CAUicmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.pngimages?q=tbn:ANd9GcQlwX77nfpy3Bu9mpMBZa0miWT2sRt2zjAPJKg2V69ODTrjZM1nT1BbhWzTVPsTNKJMZzQ&usqp=CAU


images?q=tbn:ANd9GcTaWSousoprPWGwE-qxwxGH2y0ByZ_zdLMN-Oq93MsZpBVFOTfxi9uXV7tdr39qvyE-U0I&usqp=CAU






The
 
indexes/platforms of the journal are;

TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit 


EBSCO, DOAJ, OAJI is under evaluation.

Journal articles are evaluated as "Double-Blind Peer Review"